Showing results (31-40 of 107) with videos related to
Sort By:
Pageof 11
American Journal of Hematology|January 2, 2025
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce ResistanceJennifer E Bruno, Christine A Herne, Andrea M Baran, et al.Blood|March 11, 2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaJennifer R Brown, Jacqueline C Barrientos, Paul M Barr, et al.Leukemia & Lymphoma|March 1, 2022
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphomaTanya Siddiqi, Steven Coutre, Matthew McKinney, et al.The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.American Journal of Hematology|December 22, 2017
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806Daniel O Persky, Hongli Li, Lisa M Rimsza, et al.The Oncologist|July 27, 2019
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet NeedsMatthew J Matasar, Stefano Luminari, Paul M Barr, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Pageof 11